UTHR FY 2021 Earnings Report — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

United Therapeutics CorporationUTHR

FY 2021 Earnings

Reported February 24, 2022

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2021	Prior Q	FY 2020	QoQ Change	YoY Change
Revenue	$1.7B	—	$1.5B	—	13.6%
Op. Income	$556M	—	$594M	—	-6.4%
Gross Margin	92.7%	—	92.7%	—	0.0pp
Net Margin	28.2%	—	34.7%	—	-6.5pp
EPS (Diluted)	$10.06	—	$11.54	—	-12.8%
Free Cash Flow	$477M	—	$696M	—	-31.4%

Revenue Flow

Item	Amount
REVENUE	$1.7B
Cost of Revenue	$123M
GROSS PROFIT	$1.6B
R&D Expenses	$540M
Selling & Marketing	$64M
General & Administrative	$403M
SG&A Expenses	$467M
Other Expenses	$0
Operating Expenses	$1.0B
Cost & Expenses	$1.1B
OPERATING INCOME	$556M
Interest Income	$17M
Interest Expense	$19M
Other Income/Expenses	$38M
INCOME BEFORE TAX	$594M
Income Tax Expense	$118M
Net Income from Continuing Ops	$476M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$476M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$476M
D&A	$50M
EBIT	$687M
EBITDA	$737M
EPS	$11
EPS Diluted	$10

Income Statement

Item	Amount
REVENUE	$1.7B
Cost of Revenue	$123M
GROSS PROFIT	$1.6B
R&D Expenses	$540M
Selling & Marketing	$64M
General & Administrative	$403M
SG&A Expenses	$467M
Other Expenses	$0
Operating Expenses	$1.0B
Cost & Expenses	$1.1B
OPERATING INCOME	$556M
Interest Income	$17M
Interest Expense	$19M
Other Income/Expenses	$38M
INCOME BEFORE TAX	$594M
Income Tax Expense	$118M
Net Income from Continuing Ops	$476M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$476M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$476M
D&A	$50M
EBIT	$687M
EBITDA	$737M
EPS	$11
EPS Diluted	$10

Cash Flow Statement

Item	Amount
Net Income	$476M
Depreciation & Amortization	$50M
Stock-Based Compensation	$139M
Deferred Income Tax	$0
Other Non-Cash Items	$108M
Change in Working Capital	-$174M
OPERATING CASH FLOW	$598M
Capital Expenditure	-$121M
Acquisitions (Net)	$0
Purchases of Investments	-$1.9B
Sales/Maturities of Investments	$1.5B
Other Investing Activities	$0
NET CASH FROM INVESTING	-$487M
Net Debt Issuance	$0
Common Stock Repurchased	-$11M
Common Dividends Paid	$0
Other Financing Activities	$56M
NET CASH FROM FINANCING	$45M
FREE CASH FLOW	$477M
Net Change in Cash	$156M

Balance Sheet

Item	Amount
Cash & Equivalents	$895M
Short-Term Investments	$1.0B
Net Receivables	$199M
Inventory	$94M
Other Current Assets	$100M
TOTAL CURRENT ASSETS	$2.3B
PP&E (Net)	$781M
Goodwill	$28M
Intangible Assets	$17M
Long-Term Investments	$1.6B
Tax Assets	$262M
Other Non-Current Assets	$108M
TOTAL NON-CURRENT ASSETS	$2.8B
TOTAL ASSETS	$5.2B
Account Payables	$4M
Short-Term Debt	$0
Deferred Revenue	$0
Other Current Liabilities	$248M
TOTAL CURRENT LIABILITIES	$305M
Long-Term Debt	$800M
Deferred Revenue NC	$0
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$105M
TOTAL NON-CURRENT LIABILITIES	$905M
TOTAL LIABILITIES	$1.2B
Common Stock	$700.0K
Additional Paid-In Capital	$2.2B
Retained Earnings	$4.3B
Treasury Stock	-$2.6B
Accum. Other Comp. Income	-$23M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$4.0B
Minority Interest	$0
TOTAL EQUITY	$4.0B
TOTAL LIABILITIES & EQUITY	$5.2B
Total Debt	$800M
Net Debt	-$95M